Jeff Baxter, VBI Vaccines CEO

First shot at pan-coro­n­avirus vac­cine dis­ap­points in VBI Vac­cines study

The first da­ta from a clin­i­cal tri­al of a vac­cine de­signed to pro­tect against many kinds of coro­n­avirus­es sug­gest that ef­forts to sig­nif­i­cant­ly im­prove over ex­ist­ing Covid-19 shots will be ham­pered by high lev­els of im­mu­ni­ty that many peo­ple al­ready have to the virus.

The re­sults of the 101-per­son study con­duct­ed by VBI Vac­cines were dis­closed Wednes­day morn­ing in a press re­lease. The an­nounce­ment, which was light on de­tails, said that the pan-coro­n­avirus vac­cine boost­ed an­ti­bod­ies against mul­ti­ple vari­ants of SARS-CoV-2 as well as coro­n­avirus­es that in­fect bats and pan­golins.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.